{"entity":{"id":"paper-empower-cervical-1-cemiplimab-nejm-2022","kind":"paper","name":"EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum","aka":[],"tldr":"The PD-1 antibody cemiplimab lengthened survival compared with single-agent chemotherapy in recurrent cervical cancer after platinum, regardless of PD-L1 expression, the first immunotherapy to show a survival benefit in this disease.","summary":"Phase 3 trial of 608 patients with recurrent cervical cancer progressing after first-line platinum chemotherapy randomised to cemiplimab or investigator's choice single-agent chemotherapy, enrolled irrespective of PD-L1 status.\n\nMedian overall survival was 12.0 versus 8.5 months (hazard ratio 0.69) overall and 11.1 versus 8.8 months in squamous cell carcinoma; response was 16.4 versus 6.3 percent, and benefit was seen across PD-L1 levels.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2022","url":"https://doi.org/10.1056/NEJMoa2112187"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35139273/"}],"tags":[],"related":[],"cancers":["recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["empower-cervical-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2022,"doi":"10.1056/NEJMoa2112187","pmid":"35139273","authors":"Tewari KS, Monk BJ, Vergote I, et al.","paperType":"rct","findings":["Median overall survival 12.0 vs 8.5 months; hazard ratio 0.69.","Objective response 16.4 percent vs 6.3 percent."],"whatItMeans":"Cemiplimab is an option for second-line cervical cancer in patients who have not had immunotherapy, though most now receive pembrolizumab first line, moving cemiplimab later or out of sequence.","caveats":["Patients were immunotherapy-naive; applicability after first-line pembrolizumab is unclear."],"changedPractice":true,"participants":608},"route":"/key-papers/paper-empower-cervical-1-cemiplimab-nejm-2022/","neighbours":{"cancer":[{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"trial":[{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}